Hepatic angiomyolipoma: identification of an efferent vessel as a hepatic vein by contrast-enhanced harmonic sonography
Rong Qin Zheng(Sun Yat-sen University), Kiyoshi Maekawa(Kindai University), Chikara Ogawa, Yasunori Minami, Masayuki Kitano(Wakayama Medical University), Masatoshi Kudo(Kindai University), Emi Ishikawa(Kyowa Chemical Industry (Japan)), Yasuhiro Sakaguchi(Jikei University Kashiwa hospital), Toshihiko Kawasaki(Kindai University), Hobyung Chung(Kindai University)
Cited by 3
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k